Researchers have developed a cell-based UV-A detection tool that may make sunscreen testing faster, cheaper, and more consistent — without human volunteers.
A single human cell, engineered to glow when ultraviolet light strikes it, sits at the centre of a new approach to sunscreen testing. The method, published in the Journal of Investigative Dermatology, could change how UV-blocking products are evaluated before they reach the people who need them most.
The current gold standard for sunscreen evaluation relies on human volunteers. Researchers apply products to live skin, expose it to UV radiation, and measure the response. According to the study, this process is empirically variable, ethically contested, and slow — a combination that has frustrated efforts to bring more consistent sun protection to market.
The research team developed an alternative they call AURA — Assay for UV-A Radiation Assessment. The platform uses human cells that have been genetically modified to produce light when exposed to UV-A radiation in the 320–400 nanometre range. The cells contain a photocleavable protein domain fused to two molecular switches that control gene expression. When UV-A hits the cell, the protein cleaves, the switches activate, and the cell luminesces. The brighter the glow, the greater the UV-A exposure.
The design includes what the researchers describe as nuclear export signals — molecular instructions that keep the system quiet in the absence of light, reducing false readings and improving precision.
Why this matters for sunscreen access
For people with albinism, effective sun protection is not a cosmetic choice. Melanin, the pigment absent or reduced in people with albinism, is the body's primary physical barrier against UV radiation. Without it, unprotected skin absorbs UV-A and UV-B in full, with cumulative consequences for skin health over a lifetime.
The sunscreens available in many regions — particularly across Sub-Saharan Africa and parts of Latin America — are not always tested to consistent international standards. A faster, more affordable, and more reproducible testing platform could help manufacturers and regulators verify product performance without the cost and complexity of human trials. The study reported that AURA is designed for high-throughput use, meaning many formulations can be assessed in parallel rather than one at a time.
The research does not claim that AURA is ready to replace existing regulatory frameworks. What the authors describe is a platform that could complement current methods, offering a more standardised first-pass evaluation before products move into clinical testing.
The findings add a specific, measurable tool to a field where consistency has long been difficult to achieve.
Keywords
Core topics and entities mentioned in this summary.